NADAC acquisition cost data for ABILIFY 5 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
| 59148000713 | $18.68 | 2021-12-15 | Rx |
Generic: Aripiprazole | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $26.9M | 20,939 | 3,670 | $33.40 |
| 2020 | $24.5M | 17,689 | 2,532 | $34.44 |
| 2021 | $20.5M | 15,261 | 2,174 | $32.66 |
| 2022 | $13.1M | 13,586 | 1,920 | $23.11 |
| 2023 | $11.9M | 12,115 | 1,736 | $23.32 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.7M | 1,833 | 229 |
| California | $1.7M | 1,522 | 234 |
| Texas | $748.1K | 669 | 123 |
| Florida | $731.3K | 776 | 115 |
| Massachusetts | $600.5K | 634 | 84 |
| Pennsylvania | $563.8K | 592 | 86 |
| New Jersey | $470.1K | 492 | 73 |
| North Carolina | $381.6K | 388 | 63 |
| Minnesota | $310.1K | 298 | 46 |
| Wisconsin | $297.9K | 317 | 37 |
| Michigan | $279.7K | 234 | 41 |
| Puerto Rico | $269.9K | 354 | 36 |
| Washington | $264.8K | 290 | 36 |
| Connecticut | $252.0K | 185 | 33 |
| Illinois | $224.3K | 232 | 49 |
| Indiana | $202.2K | 181 | 29 |
| Arizona | $192.3K | 203 | 35 |
| Georgia | $187.1K | 180 | 36 |
| Tennessee | $168.6K | 197 | 26 |
| Ohio | $162.7K | 203 | 37 |
| South Carolina | $156.4K | 180 | 32 |
| Kentucky | $154.8K | 182 | 24 |
| Colorado | $153.5K | 154 | 30 |
| Virginia | $141.1K | 173 | 32 |
| Missouri | $139.4K | 156 | 25 |
| Iowa | $135.2K | 158 | 19 |
| Maryland | $118.0K | 90 | 22 |
| Utah | $113.0K | 93 | 14 |
| Oregon | $106.7K | 103 | 14 |
| Maine | $92.2K | 75 | 11 |
| New Hampshire | $89.8K | 94 | N/A |
| Kansas | $89.2K | 89 | 15 |
| Louisiana | $66.4K | 72 | 17 |
| Nebraska | $61.6K | 44 | N/A |
| Nevada | $59.1K | 60 | N/A |
| Alabama | $53.5K | 58 | N/A |
| Rhode Island | $48.6K | 77 | N/A |
| Idaho | $45.4K | 52 | N/A |
| Montana | $42.4K | 57 | N/A |
| West Virginia | $42.1K | 35 | N/A |
| New Mexico | $39.0K | 26 | N/A |
| Oklahoma | $34.9K | 42 | N/A |
| Vermont | $33.2K | 37 | N/A |
| Alaska | $32.9K | 16 | N/A |
| Wyoming | $32.3K | 25 | N/A |
| Mississippi | $31.5K | 39 | N/A |
| North Dakota | $24.9K | 27 | N/A |
| District of Columbia | $23.0K | 19 | N/A |
| Hawaii | $18.6K | 22 | N/A |
| Arkansas | $18.2K | 18 | N/A |
| Delaware | $15.6K | 23 | N/A |
| South Dakota | $9.7K | 20 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.